NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

MelanomaNon-small Cell Lung Carcinoma (NSCLC)Renal Cell Carcinoma (RCC)Small-cell Lung CancerHead and Neck Squamous Cell CancerClassical Hodgkin LymphomaPrimary Mediastinal Large B-Cell LymphomaUrothelial CarcinomaMicrosatellite Instability-High CancerGastric CancerEsophageal CancerCervical CancerHepatocellular CarcinomaMerkel Cell CarcinomaBrain Metastases, Adult

Interventions

COMBINATION_PRODUCT

LITT + Pembrolizumab

Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.

Trial Locations (2)

32209

University of Florida Health, Jacksonville

32611

McKnight Brain Institute of the University of Florida, Gainesville